ERBB2 and breast cancer: In fact, nearly 25% of HER2+ breast cancer patients experience a significant decline in asymptomatic LVEF and as many as 4.0% of patients experience symptomatic heart failure (Romond et al., 2012; Goldhirsch et al., 2013).